TACSTD2 and non-small cell lung carcinoma: Datopotamab deruxtecan (Dato-DXd, DS-1062a), a TROP2-targeting ADC showed satisfactory results for the treatment of NSCLC in a phase I study, and this ADC is being further evaluated in the TROPION-Lung 02 and TROPION-Lung 05 trials [224].